Trivalent virosomal influenza vaccine

BIOLOGICAL2 trials

Sponsors

Solvay Pharmaceuticals, Crucell Holland BV

Conditions

Healthy VolunteersInfluenza

Phase 1

Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults

CompletedNCT02148328

Crucell Holland BVInfluenza

Start: 2014-05-31End: 2014-10-31Updated: 2014-10-24

Phase 3

Annual Study to Investigate Inactivated Virosomal Influenza Vaccine for the 2006/2007 Influenza Season in Europe.

WithdrawnNCT00345462

Solvay PharmaceuticalsHealthy Volunteers

Start: 2006-06-30Target: 120Updated: 2010-02-08